Building Targeted Chemotherapies: ADCs, ProTides And ‘Click Chemistry’

If targeted therapies for cancer represent a more precise, laser-like attack on solid tumors and blood cancers, cytotoxic chemotherapies are more like a ham-fisted boxer punching every cell in sight. New methods for delivering chemotherapy directly into cancer cells may help to improve efficacy and reduce – or eliminate – damaging and sometimes deadly side effects.    

Howard Skipper, early cancer chemotherapy researcher
Early Chemotherapy Researcher Howard Skipper

Antibody-drug conjugates (ADCs), which pair a chemotherapy agent with a monoclonal antibody using a chemical linker, are designed to target a specific antigen present on the surface of cancer cells. This approach aims to circumvent the fundamental problem with chemotherapies, which is the damage they can do to healthy, noncancerous cells. Chemotherapy’s destruction of healthy cells can trigger a long list of adverse events, from hair loss, fatigue and nausea, to peripheral neuropathy, cognitive disfunction and heart failure.

Research and development of ADCs for cancer is a growing sector of activity; after Wyeth’s (now Pfizer’s) Mylotarg (gemtuzumab ozogamicin)...

More from Innovation

Rising Leaders 2025: How Christina Smolke Turned Research Into Real World Impact

 
• By 

The Stanford professor-turned-CEO's 15-year journey demonstrates how scientific vision and focused leadership can revolutionize pharmaceutical supply chains.

AI In The Loop: How Astellas Is Accelerating Oncology Drug Discovery

 
• By 

Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.

BioBytes: Israeli-US Startup Introduces Platform For Accelerated Clinical Data Analysis

 
• By 

A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.

The Dementia Disparity: Rethinking Alzheimer’s Through The Female Lens

 
• By 

Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.

More from In Vivo

AI In The Loop: How Astellas Is Accelerating Oncology Drug Discovery

 
• By 

Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.

BioBytes: Israeli-US Startup Introduces Platform For Accelerated Clinical Data Analysis

 
• By 

A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.

The Dementia Disparity: Rethinking Alzheimer’s Through The Female Lens

 
• By 

Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.